Lifecore Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Firm submits amendment to a premarket approval application for its Intergel adhesion prevention barrier that responds to "all questions raised" by FDA's General and Plastic Surgery Devices Advisory Panel in January (1"The Gray Sheet" Jan. 17, p. 4). The panel cited higher than expected infection rates and deficiencies in the statistical analysis conducted by the company among the reasons FDA should not approve the firm's PMA
You may also be interested in...
Data Deficiencies Derail Lifecore Intergel Liquid Adhesion Barrier PMA
Higher than expected infection rates, pending safety data and lingering questions over clinical efficacy prompted FDA's General and Plastic Surgery Devices Panel to recommend against approval of Lifecore Biomedical's Intergel adhesion prevention barrier solution in a 5-2 vote during a Jan. 12 meeting in Rockville, Maryland.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.